DIVIS LABORATORIES
Quarterly Results Analysis [Mar2025]
DIVIS LABORATORIES Quarterly Results
Consolidated | Mar2025 UnAudited |
Dec2024 UnAudited |
Sep2024 UnAudited |
Jun2024 Audited |
Mar2024 UnAudited |
Dec2023 UnAudited |
Sep2023 UnAudited |
Jun2023 UnAudited |
---|---|---|---|---|---|---|---|---|
Revenues | ₹2,585 Cr | ₹2,319 Cr | ₹2,338 Cr | ₹2,118 Cr | ₹2,303 Cr | ₹1,855 Cr | ₹1,909 Cr | ₹1,778 Cr |
Expenses | ₹1,699 Cr | ₹1,576 Cr | ₹1,622 Cr | ₹1,496 Cr | ₹1,572 Cr | ₹1,366 Cr | ₹1,430 Cr | ₹1,274 Cr |
Operating Income | ₹886 Cr | ₹743 Cr | ₹716 Cr | ₹622 Cr | ₹731 Cr | ₹489 Cr | ₹479 Cr | ₹504 Cr |
Other Income | ₹86 Cr | ₹82 Cr | ₹106 Cr | ₹79 Cr | ₹79 Cr | ₹95 Cr | ₹86 Cr | ₹81 Cr |
Interest | ₹1 Cr | ₹0 Cr | ₹1 Cr | ₹0 Cr | ₹2 Cr | ₹0 Cr | ₹1 Cr | ₹0 Cr |
Depreciation | ₹107 Cr | ₹99 Cr | ₹99 Cr | ₹97 Cr | ₹95 Cr | ₹95 Cr | ₹95 Cr | ₹93 Cr |
Profit Before Tax | ₹864 Cr | ₹726 Cr | ₹722 Cr | ₹604 Cr | ₹713 Cr | ₹489 Cr | ₹469 Cr | ₹492 Cr |
Profit After Tax | ₹662 Cr | ₹589 Cr | ₹510 Cr | ₹430 Cr | ₹538 Cr | ₹358 Cr | ₹348 Cr | ₹356 Cr |
EPS | ₹24.98 | ₹22.23 | ₹19.25 | ₹16.23 | ₹20.30 | ₹13.51 | ₹13.13 | ₹13.43 |
Industry Peers & Returns | 1W | 1M | 1Y |
DIVIS LABORATORIES | 1.5% | 10.4% | 51.9% |
SUN PHARMACEUTICAL INDUSTRIES | 1.6% | -2.9% | 17.2% |
CIPLA | 2.3% | 1.9% | 2.8% |
TORRENT PHARMACEUTICALS | 1.4% | 1.3% | 17% |
DR REDDYS LABORATORIES | 5.7% | 14.1% | 15.2% |
MANKIND PHARMA | 0.2% | -2.4% | 12.5% |
ZYDUS LIFESCIENCES | 5.1% | 10.9% | -4.4% |
LUPIN | 2% | -2.2% | 27.9% |
AUROBINDO PHARMA | 1.5% | -0.2% | -3.3% |
DIVIS LABORATORIES Quarterly Revenues
Revenues | |
---|---|
Q-o-Q | 11.47 % |
Y-o-Y | 12.24 % |
Quarters | Revenues | % Change | |
---|---|---|---|
Mar2025 | ₹2,585 Cr | 11.47 | |
Dec2024 | ₹2,319 Cr | -0.81 | |
Sep2024 | ₹2,338 Cr | 10.39 | |
Jun2024 | ₹2,118 Cr | -8.03 | |
Mar2024 | ₹2,303 Cr | 24.15 | |
Dec2023 | ₹1,855 Cr | -2.83 | |
Sep2023 | ₹1,909 Cr | 7.37 | |
Jun2023 | ₹1,778 Cr | - |
DIVIS LABORATORIES Quarterly Operating Profit
Operating Profit | |
---|---|
Q-o-Q | 19.25 % |
Y-o-Y | 21.20 % |
Quarters | Operating Profit | % Change | |
---|---|---|---|
Mar2025 | ₹886 Cr | 19.25 | |
Dec2024 | ₹743 Cr | 3.77 | |
Sep2024 | ₹716 Cr | 15.11 | |
Jun2024 | ₹622 Cr | -14.91 | |
Mar2024 | ₹731 Cr | 49.49 | |
Dec2023 | ₹489 Cr | 2.09 | |
Sep2023 | ₹479 Cr | -4.96 | |
Jun2023 | ₹504 Cr | - |
Operating Margins | |
---|---|
Q-o-Q | 6.96 % |
Y-o-Y | 7.97 % |
Quarters | Operating Margin% | % Change | |
---|---|---|---|
Mar2025 | 34.27% | 6.96 | |
Dec2024 | 32.04% | 4.64 | |
Sep2024 | 30.62% | 4.26 | |
Jun2024 | 29.37% | -7.47 | |
Mar2024 | 31.74% | 20.41 | |
Dec2023 | 26.36% | 5.06 | |
Sep2023 | 25.09% | -11.50 | |
Jun2023 | 28.35% | - |
DIVIS LABORATORIES Quarterly Profit After Tax
Profit After Tax(PAT) | |
---|---|
Q-o-Q | 12.39 % |
Y-o-Y | 23.05 % |
Quarters | Profit After Tax | % Change | |
---|---|---|---|
Mar2025 | ₹662 Cr | 12.39 | |
Dec2024 | ₹589 Cr | 15.49 | |
Sep2024 | ₹510 Cr | 18.60 | |
Jun2024 | ₹430 Cr | -20.07 | |
Mar2024 | ₹538 Cr | 50.28 | |
Dec2023 | ₹358 Cr | 2.87 | |
Sep2023 | ₹348 Cr | -2.25 | |
Jun2023 | ₹356 Cr | - |
PAT Margins | |
---|---|
Q-o-Q | 0.83 % |
Y-o-Y | 9.63 % |
Quarters | PAT Margin(%) | % Change | |
---|---|---|---|
Mar2025 | 25.61 % | 0.83 | |
Dec2024 | 25.4 % | 16.46 | |
Sep2024 | 21.81 % | 7.44 | |
Jun2024 | 20.3 % | -13.10 | |
Mar2024 | 23.36 % | 21.04 | |
Dec2023 | 19.3 % | 5.87 | |
Sep2023 | 18.23 % | -8.94 | |
Jun2023 | 20.02 % | - |
DIVIS LABORATORIES Quarterly Earnings Per Share (EPS)
EPS | |
---|---|
Q-o-Q | 12.37 % |
Y-o-Y | 23.05 % |
Quarters | EPS | % Change | |
---|---|---|---|
Mar2025 | ₹24.98 | 12.37 | |
Dec2024 | ₹22.23 | 15.48 | |
Sep2024 | ₹19.25 | 18.61 | |
Jun2024 | ₹16.23 | -20.05 | |
Mar2024 | ₹20.3 | 50.26 | |
Dec2023 | ₹13.51 | 2.89 | |
Sep2023 | ₹13.13 | -2.23 | |
Jun2023 | ₹13.43 | - |
You may also like the below Video Courses
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs MANKIND PHARMA LTD